An Open-label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics or Preliminary Efficacy and Antitumor Activity of GNC-077 Multi-specific Antibody Injection in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
Overview
- Phase
- Phase 1
- Intervention
- GNC-077
- Conditions
- Gastrointestinal Tumors
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Phase Ia: Dose limiting toxicity (DLT)
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
This study is an open-label, multicenter, dose-escalation and cohort expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics or preliminary efficacy and antitumor activity in patients with locally advanced or metastatic gastrointestinal tumors and other solid tumors.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Able to understand the informed consent form, voluntarily participate in and sign the informed consent form;
- •Gender is not limited;
- •Age: ≥18 years old and ≤75 years old (phase Ia); ≥18 years old (phase Ib);
- •Patients with locally advanced or metastatic gastrointestinal tumors and other solid tumors confirmed by histopathology and/or cytology who failed standard treatment;
- •Must have at least one measurable lesion that meets the RECIST v1.1 definition;
- •Have archived primary or recurrent tumor tissue specimens that can be submitted for central review;
- •The expected survival time as judged by the investigators was ≥3 months;
- •Bone marrow function, renal function and liver function need to meet the requirements;
- •Coagulation function: fibrinogen ≥1.5 g/L; Activated partial thromboplastin time (APTT) ≤1.5×ULN; Prothrombin time (PT) ≤1.5×ULN;
- •Fertile female subjects or male subjects with fertile partners must use highly effective contraception from 7 days before the first dose until 12 weeks after the last dose. Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose;
Exclusion Criteria
- •Chemotherapy, biological therapy, immunotherapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose; Mitomycin and nitrosoureas were administered within 6 weeks before the first dose; Oral drugs such as fluorouracil;
- •Patients with active infection requiring intravenous antibiotics that had not been completed more than 1 week before enrollment, with the exception of prophylactic antibiotics for puncture or biopsy;
- •Positive human immunodeficiency virus antibody, active tuberculosis, active hepatitis B virus infection or hepatitis C virus infection;
- •Toxicity from prior antineoplastic therapy is not reduced to grade I as defined in CTCAE, version 5.0;
- •Patients at risk for active autoimmune disease or with a history of autoimmune disease may have central nervous system involvement;
- •Pulmonary disease defined as ≥ grade 3 according to NCI-CTCAE v5.0; A history of ILD requiring steroid therapy, or current ILD or grade ≥2 radiation pneumonitis;
- •Patients with previous allogeneic hematopoietic stem cell transplantation or organ transplantation;
- •Had a history of severe cardiovascular and cerebrovascular diseases;
- •Patients with or with unstable thrombotic events such as deep vein thrombosis, arterial thrombosis and pulmonary embolism within 6 months before screening;
- •Brain parenchymal metastases and/or meningeal metastases or spinal cord compression, excluding stable and asymptomatic brain parenchymal metastases;
Arms & Interventions
GNC-077
Participants receive GNC-077 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
Intervention: GNC-077
Outcomes
Primary Outcomes
Phase Ia: Dose limiting toxicity (DLT)
Time Frame: Up to 21 days after the first dose
DLTs are assessed according to NCI-CTCAE v5.0 during the first cycle and defined as occurrence of any of the toxicities in DLT definition if judged by the investigator to be possibly, probably or definitely related to study drug administration.
Phase Ia: Maximum tolerated dose (MTD)
Time Frame: Up to 21 days after the first dose
MTD is defined as the highest dose level at which no more than 1 in 6 participants experienced a DLT during the first cycle.
Phase Ia: Treatment-Emergent Adverse Event (TEAE)
Time Frame: Up to approximately 24 months
TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of GNC-077 . The type, frequency and severity of TEAE will be evaluated during the treatment of GNC-077.
Phase Ib: Recommended Phase II Dose (RP2D)
Time Frame: Up to approximately 24 months
The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of GNC-077.
Secondary Outcomes
- Cmax(Up to approximately 24 months)
- Tmax(Up to approximately 24 months)
- AUC0-inf(Up to approximately 24 months)
- AUC0-t(Up to approximately 24 months)
- CL (Clearance)(Up to approximately 24 months)
- T1/2(Up to approximately 24 months)
- ADA (anti-drug antibody)(Up to approximately 24 months)
- Objective Response Rate (ORR)(Up to approximately 24 months)
- Progression-free survival (PFS)(Up to approximately 24 months)